Back to top

CalciMedica announces FDA alignment on Phase 2b Auxora trial design

CalciMedica (CALC) announced that, following a Type C Focused Meeting, the U.S. Food and Drug Administration and the company have aligned on Phase ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CalciMedica Inc. (CALC)